The 10 mg once-daily dose of rivaroxaban (Xarelto) has been approved by the FDA for reducing continued risk for recurrent venous thromboembolism (VTE) after patients complete at least 6 months of initial anticoagulation therapy. | Read More

The safety and conversion rate of the VenaTech Convertible filter were evaluated in a prospective, multicenter trial. | Read More

Researchers compared treatment with paclitaxel–resveratrol-matrix-coated peripheral balloon angioplasty versus plain old balloon angioplasty in patients with symptomatic peripheral artery occlusive disease in femoro-popliteal lesions. | Read More

Researchers compared ultrasound-accelerated endovascular thrombolysis (USAT) and pigtail catheter-directed thrombolysis (PCDT) for the treatment of acute pulmonary embolism (PE), and they found that the techniques are similarly effective and safe. | Read More

The official news source for the International Symposium on Endovascular Therapy (ISET) providing information on the latest advancements in peripheral vascular disease treatment. | Read More

A novel device was able to prevent clinically significant pulmonary embolism (PE) and fatal PE in critically ill trauma patients. | Read More

Morristown Medical Center Randomizes First Patient in World to New Study to Evaluate Treatment for Asymptomatic Severe Aortic Stenosis | Read More

Joint Commission Compendium of Resources is Now Available to the Public for Free | Read More

Bothell, WA, 22 May 2017: BTG plc (LSE: BTG), the global specialist healthcare company, today highlights the results of the OPTALYSE PE trial, presented at the American Thoracic Society International Conference in Washington, D.C. | Read More